Chugai Pharmaceutical's Antitumor Agent Natulan Now Available for Treating Glioma

Tokyo (JCNN) - Chugai Pharmaceutical (TSE: 4519) has announced that it has received approval for expanded indications of Natulan, an antitumor agent, from the Ministry of Health, Labor and Welfare (Japan).

The newly approved agent is now applicable to the treatment of glioma with malignant astrocytoma and oligodendroglioma.

Developed by F. Hoffmann-La Roche, Natulan, a methylhydrazine compound, has been used in the treatment of malignant lymphoma since 1977.

View Chugai Pharmaceutical Co., Ltd. company profile here

Copyright © 2001-2004 JCNN. All rights reserved. A division of Japan Corporate News Network KK.

Provided via: http://www.i-newswire.com
If you have questions regarding information in these press release contact the company listed below. I-Newswire.com is a press release service and not the author of this press release. The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies / PR Agencies submit their press releases once per week/month or quarter, make sure check the official company website for accurate release dates as our site displays the I-Newswire.com distribution date only. We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.